AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...

Kissei Pharmaceutical is paying Viridian Therapeutics $70 million upfront for Japanese rights to a pair of thyroid eye ...

Amgen Inc. (AMGN) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, AMGN's 50-day simple moving average broke out above its 200-day ...

Osborne Clarke has posted a global revenue increase of 4% to €547.5 million for the 2024/25 financial year. The firm ...

The firms posted increases in revenue and profit per equity partner, with both giving a nod to their IP expertise ...

Drugmaker struggled to adapt to very high demand and a market where celebrities are more influential than doctors ...

The global bispecific antibodies market, valued at USD 5.6 billion in 2025, is set to soar to USD 16.8 billion by 2035, growing at a CAGR of 9.5%. Key drivers include advancements in monoclonal ...

Amgen (AMGN) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good ...

Paul McGinley was one of the heavy hitters in the golf and business community invited to help US President Donald Trump open his new Aberdeenshire golf course.

Nasdaq and S&P 500 hit record highs on Wall Street on Tuesday, 29 July 2025, as investors focused on the second-quarter ...

South Korea’s biopharmaceutical sector has seen a surge in innovator drug licensing agreements, reaching a total deal value of $7.86bn in 2025 year-to-date (YTD), at a 113% increase from 2024, ...

Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET IGNITE trial of rocatinlimab, an investigational ...